EBPC – 1 mg

Brand:
Cayman
CAS:
4450-98-0
Storage:
-20
UN-No:
Non-Hazardous - /

The human aldose reductase AKR1B1 is considered the rate limiting enzyme of the polyol pathway responsible for the conversion of glucose into sorbitol. It also acts as a highly efficient PGF2α synthase in response to interleukin-1β.{22416} Increased aldose reductase expression has been associated with complications of diabetes and may contribute to reduced efficacy of certain chemotherapeutic drugs.{22417} EBPC is a potent, selective inhibitor of aldose reductase with an IC50 value of 47 nM in vitro.{22415} Through its regulation of glucose metabolism, EBPC has been used to improve the cytotoxic effects of the anticancer agents doxorubicin and cisplatin in HeLa cervical carcinoma cells.{22417} EBPC also inhibits prostaglandin F2α (PGF2α) and PGE2 production in human endometrial cells with an EC50 value of 10 μM.{22416}  

 

SKU: - Category:

Description

A potent, selective inhibitor of aldose reductase (IC50 = 47 nM in vitro) used to improve the cytotoxic effects certain anticancer agents; inhibits PGF2α and PGE2 production in human endometrial cells (EC50 = 10 μM)


Formal name: 2,5-dihydro-4-hydroxy-5-oxo-1-(phenylmethyl)-1H-pyrrole-3-carboxylic acid, ethyl ester

Synonyms:  NSC 229530

Molecular weight: 261.3

CAS: 4450-98-0

Purity: ≥98%

Formulation: A crystalline solid


Application|Enzyme Activity||Product Type|Biochemicals|Small Molecule Inhibitors|Prostaglandin Synthases||Research Area|Cancer||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism